Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

Published:2017-09-18 Issue:11 Volume:108 Page:2213-2220
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Nishio Shin¹^ORCID,Takekuma Munetaka²,Takeuchi Satoshi³,Kawano Kouichirou¹,Tsuda Naotake¹,Tasaki Kazuto¹,Takahashi Nobutaka²,Abe Masakazu²,Tanaka Aki²,Nagasawa Takayuki³,Shoji Tadahiro³,Xiong Hao⁴,Nuthalapati Silpa⁴,Leahy Terri⁴,Hashiba Hideyuki⁵,Kiriyama Tsukasa⁵,Komarnitsky Philip⁴,Hirashima Yasuyuki²,Ushijima Kimio¹

Affiliation:

1. Department of Obstetrics and Gynecology Kurume University School of Medicine Kurume, FukuokaJapan

2. Division of Gynecology Shizuoka Cancer Center Nagaizumi, ShizuokaJapan

3. Department of Obstetrics and Gynecology Iwate Medical University School of Medicine Morioka Iwate Japan

4. AbbVie North Chicago Illinois USA

5. AbbVie GK Tokyo Japan

Funder

AbbVie

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13381

Reference32 articles.

1. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

2. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

3. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

4. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

5. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies;SN Comprehensive Clinical Medicine;2023-07-06

2. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620);Breast Cancer Research and Treatment;2023-02-28

3. Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum–Paclitaxel Chemotherapy: A Meta-Analysis;Clinical Oncology;2023-02

4. Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial;International Journal of Clinical Oncology;2022-12-19

5. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities;International Journal of Molecular Sciences;2022-11-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3